Want to see SRZN full AI Analyst Report?
Top Page
Surrozen
(NASDAQ:SRZN)
Select Model
Select Model
Rating:46Neutral
Price Target:
$29.00
▲(24.14% Upside)
Action:Reiterated
Date:10/21/26
The score is primarily weighed down by very weak financial performance (large losses, persistent cash burn, and negative equity), which dominates the risk profile. Technicals are mixed-to-soft with the stock below its 20-day average and neutral RSI. Positive corporate events (IND clearance and a large financing extending runway) provide a meaningful offset but do not fully mitigate the underlying profitability and balance-sheet concerns, while valuation metrics remain unfavorable due to losses.
Positive Factors
Revenue rebound
The rebound in trailing revenue provides evidence of improving commercial or collaboration-related activity after a weak prior period. If sustained, a larger revenue base could help Surrozen absorb its operating costs and support development of its regenerative medicine pipeline.
Negative Factors
Extreme net losses
The very large net loss shows that Surrozen’s current cost base is far out of line with its revenue generation. Without substantial operating improvement or successful clinical and commercial outcomes, persistent losses could continue to consume capital and weaken long-term financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The rebound in trailing revenue provides evidence of improving commercial or collaboration-related activity after a weak prior period. If sustained, a larger revenue base could help Surrozen absorb its operating costs and support development of its regenerative medicine pipeline.
Read all positive factors
Surrozen (SRZN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$347.08M
Dividend YieldN/A
Average Volume (3M)923.72K
Price to Earnings (P/E)―
Beta (1Y)0.02
Revenue Growth-8.79%
EPS Growth-195.46%
CountryUS
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-41.13
Shares Outstanding11,753,558
10 Day Avg. Volume507,463
30 Day Avg. Volume923,724
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue43.86
Enterprise Value/Gross Profit44.11
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$47.50Price Target Upside103.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-7.02
Revenue Forecast (FY)$10.74M
Surrozen Business Overview & Revenue Model
Company Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including dis...
Surrozen Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
24
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.51M | 3.48M | 10.65M | 0.00 | 12.50M | 0.00 |
| Gross Profit | 11.45M | 2.94M | 10.65M | -27.23M | 9.23M | -3.30M |
| EBITDA | -331.96M | -241.49M | -62.12M | -41.13M | -34.05M | -52.58M |
| Net Income | -332.13M | -242.03M | -63.56M | -43.04M | -36.00M | -52.51M |
Balance Sheet | ||||||
| Total Assets | 115.61M | 98.73M | 48.47M | 46.08M | 89.44M | 137.17M |
| Cash, Cash Equivalents and Short-Term Investments | 102.04M | 89.25M | 34.56M | 36.04M | 75.84M | 101.85M |
| Total Debt | 6.32M | 6.64M | 8.47M | 3.38M | 5.60M | 7.79M |
| Total Liabilities | 334.27M | 286.49M | 69.85M | 8.14M | 13.43M | 27.47M |
| Stockholders Equity | -218.66M | -187.76M | -21.38M | 37.94M | 76.00M | 109.70M |
Cash Flow | ||||||
| Free Cash Flow | -34.98M | -30.37M | -17.65M | -40.76M | -44.87M | -50.08M |
| Operating Cash Flow | -34.76M | -30.24M | -17.63M | -40.36M | -44.15M | -48.81M |
| Investing Cash Flow | -222.00K | -128.00K | -26.00K | 51.72M | 38.31M | -77.71M |
| Financing Cash Flow | 46.58M | 85.05M | 16.18M | 276.00K | -2.56M | 124.63M |
Surrozen Technical Analysis
Positive
23.36
Price Trends
23.96
Positive
23.42
Positive
24.95
Positive
Market Momentum
0.70
Negative
60.65
Neutral
80.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRZN, the sentiment is Positive. The current price of 23.36 is below the 20-day moving average (MA) of 26.63, below the 50-day MA of 23.96, and below the 200-day MA of 24.95, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 60.65 is Neutral, neither overbought nor oversold. The STOCH value of 80.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRZN.
Surrozen Risk Analysis
Surrozen disclosed 85 risk factors in its most recent earnings report. Surrozen reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Surrozen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $579.10M | -11.31 | -43.57% | ― | -66.63% | 57.89% | |
53 Neutral | $441.37M | -4.71 | -23.64% | ― | -76.20% | 52.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $347.08M | -0.72 | 187.62% | ― | -8.79% | -195.46% | |
45 Neutral | $287.86M | -2.72 | 1147.63% | ― | -36.09% | 24.84% | |
44 Neutral | $46.56M | -1.29 | -171.19% | ― | ― | 83.55% | |
43 Neutral | $131.20M | -1.12 | -123.53% | ― | -100.00% | 52.43% |
* Healthcare Sector Average
SRZN
Surrozen
29.53
15.94
117.29%
IRD
Opus Genetics
3.68
1.70
85.86%
OVID
Ovid Therapeutics
2.45
1.00
68.97%
STTK
Shattuck Labs
5.77
3.82
195.90%
SPRB
Spruce Biosciences
45.65
-72.35
-61.31%
BMEA
Biomea Fusion
0.64
-0.73
-53.14%
Surrozen Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Surrozen Raises $95 Million, Extends Cash Runway
Positive
Oct 20, 2026
On October 20, 2026, Surrozen closed the second and final tranche of its March 2025 private placement, raising approximately $95.1 million in gross proceeds through a mix of common stock, pre-funded warrants and Series E warrants. The financing fo...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Surrozen Wins FDA IND Clearance for SZN-8141 Program
Positive
Oct 2, 2026
Surrozen, Inc., a biotech developer of Wnt-modulating antibody therapies, reported on October 2, 2026, that the U.S. Food and Drug Administration cleared its Investigational New Drug application for SZN-8141, an intravitreal bifunctional Wnt agoni...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.